Spironolactone potassium — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Hyperkalaemia risk
This scenario assesses Spironolactone potassium in a UK pharmacy practice context. Spironolactone is potassium-sparing and potassium supplementation may cause serious hyperkalaemia. The best answer is Hyperkalaemia risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.
Reference: BNF